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Abstract
Purpose.—To determine the patient-centeredness of endocrine and bone health Duchenne 
muscular dystrophy (DMD) care considerations using the RAND/PPMD Patient-Centeredness 
Method (RPM), which is a novel, online, modified-Delphi approach to engaging patients and 
caregivers in clinical guideline development.
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Methods.—We solicited input on the patient-centeredness of care considerations from 28 
individuals with DMD and 94 caregivers, randomly assigned to 1 of 2 mixed panels. During a 3-
round online modified-Delphi process, participants rated the importance and acceptability of 19 
DMD care considerations (round 1), reviewed and discussed the initial results (round 2), and 
revised their original ratings (round 3). Patient-centeredness was operationalized as importance 
and acceptability of recommendations. We considered a care consideration to be patient-centered 
if both panels deemed it important and acceptable.
Results.—Ninety-five panelists (78%) participated in this study. Of these, 88 (93%) participated 
in round 1, 74 (78%) in round 2, and 56 (59%) in round 3. Panelists deemed 12 care 
considerations to be patient-centered: 3 weight management, 3 bone health, 4 vertical growth, and 
2 puberty recommendations. Seven care considerations did not meet patient-centeredness criteria. 
Common reasons were lack of evidence specific to DMD and concerns about insurance coverage, 
access to treatment, and patient safety.
Conclusions.—Using the RPM, Duchenne families considered most care considerations to be 
patient-centered. Besides being clinically appropriate, these considerations are likely to be 
consistent with the preferences, needs, and values of Duchenne families. While all relevant care 
considerations should be discussed during patient-provider encounters, those that did not meet 
patient-centeredness criteria in particular should be carefully considered as part of joint decision 
making between Duchenne families and their providers.
Study Registration: HSRProj 20163126.
Keywords
clinical practice guidelines; DMD care considerations; duchenne muscular dystrophy; online 
modified-delphi; patient engagement; RAND/PPMD patient-centeredness method rhGH stands for 
recombinant human growth hormone
In 2010, the US Centers for Disease Control and Prevention (CDC) supported the 
development of the Duchenne muscular dystrophy (DMD) care considerations to help health 
care providers, affected individuals, and their families better manage this rare disorder.1,2 
DMD is a progressive, fatal neuromuscular disorder caused by mutations in the dystrophin 
gene. DMD affects approximately 1 in 5000 males,3 typically manifesting itself between 
ages 3 and 5.4 It is a multisystem disorder in which affected individuals experience 
progressive loss of functional muscle fibers, which results in weakness, loss of mobility, and 
premature death. About half of males with DMD survive into their 20s and some live into 
their 30s and 40s.5 As the condition runs its course, caregiving, financial, emotional, and 
physical demands increase and affect the entire family.6–8
The DMD care considerations, or care guidelines, as they are commonly called in the 
Duchenne community,9 were revised in 2018 to incorporate new evidence and guidance on 
primary and emergency care, transition of care/adult care, and endocrine and bone health 
management.10–12 (In this article, we use the terms guidance and care considerations when 
referring to the 2018 DMD care considerations. When referring to the development of 
clinical guidelines in general, we use the terms guidelines and recommendations 
interchangeably.) Clinical experts achieved consensus through reviewing the existing 
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evidence and using the RAND/UCLA Appropriateness Method (RAM)13 to rate the clinical 
appropriateness and necessity of different approaches to providing care. Because RAM does 
not require patient involvement when rating evidence or inclusion of evidence about patient 
preferences, individuals with DMD and their families did not directly participate in 
developing most sections of the care considerations.
Although there are commonly accepted practices for synthesizing research, clinical, and 
economic evidence for clinical guideline development purposes,14,15 there is less clarity on 
how best to integrate patient-based evidence or information generated by patients about 
different aspects of care, patient preferences, and care experiences.16–18 Doing so is 
important because patient involvement in developing care guidelines enhances their quality 
and legitimacy17 by ensuring that guidelines focus on topics and outcomes important to 
patients, identify risks and benefits of different recommendations, and address the feasibility 
and acceptability of recommended care standards.19,20 Involving patients at what 
Concannon et al.21 call the “dissemination and application” stage of patient-centered 
outcomes research can also facilitate the use of guidelines in practice. There is no consensus 
on whether patients should be equal members of guideline groups or if patient input and 
preferences should just be shared with clinicians on guideline groups.17 This lack of 
consensus may reflect the challenges of engaging patients at the population level.22 It may 
also reflect the lack of systematic, low-burden approaches to engagement that can solicit 
patient-based evidence in a way that is consistent with how clinicians develop guidelines but 
does not require travel and extensive training and support.19,23
The main objective of this study is to use a new scalable online approach for engaging 
patients and caregivers in guideline development called the RAND/PPMD Patient-
Centeredness Method (RPM)24 to determine what individuals with DMD and their 
caregivers think about the patient-centeredness of the 2018 DMD care considerations. We 
consider patient-centeredness, operationalized as perceived importance and acceptability of 
a recommendation for a typical family, to be a form of patient-based evidence, which serves 
as a “bridge between individual and population approaches”25 to providing care. 
Systematically incorporating patient-centeredness into clinical guideline development before 
recommendations are finalized can help align evidence-based medicine with patient needs, 
values, concerns, and preferences by facilitating shared decision making.26
Methods
A month after the 2018 DMD care considerations were published,10–12 we conducted 2 
online modified-Delphi panels that solicited the perspectives of individuals with DMD and 
their caregivers on the patient-centeredness of care considerations for endocrine and bone 
health management following a prespecified study design.27 We chose to focus on endocrine 
and bone health care because this guidance was added only in 2018. It was also developed 
without direct patient or caregiver involvement. Both panels were conducted using the 
RPM24 (see below) that closely mirrors a 3-round modified-Delphi rating process of 
appropriateness and necessity that clinicians used to develop the DMD care considerations. 
We also used the guidance for conducting and reporting Delphi studies (CREDES) in 
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preparing this article.28 The RAND institutional review board reviewed and determined our 
study to be exempt.
Participants
We used the Parent Project Muscular Dystrophy’s (PPMD) “Duchenne Registry”—the 
largest patient and caregiver registry in the United States for Duchenne and Becker muscular 
dystrophy29—to recruit individuals with Duchenne and their caregivers. We considered them 
key stakeholders. We sent invitation emails describing the study to 719 potential participants 
who had logged into their registry account at least once during the previous 8 months, asking 
those interested in participating to answer basic demographic questions. We assembled a 
diverse sample of 122 participants (28 individuals with DMD and 94 caregivers) from 153 
individuals who expressed an interest in this study. By design, we included only individuals 
with DMD 18 years and older and their caregivers because some care considerations focused 
on pubertal development, and we wanted to ensure that all individuals with DMD in our 
panels have gone through puberty. We excluded those who participated in a previous pilot 
study, parents and children providing the same email address, and caregivers from the same 
household.
Because 40 to 60 participants is a recommended size for online panels,30 we randomly 
assigned selected participants to 1 of 2 panels. We balanced the panel composition in terms 
of the number of individuals with DMD and caregivers, caregiver educational attainment, 
ambulatory status of the individual with DMD, and the distance to the closest PPMD 
Certified Duchenne Care Center.31
Design
Our study uses an embedded mixed-methods design, in which quantitative data are used to 
determine patient-centeredness and qualitative data are used to explain the factors that might 
have affected participants’ ratings of patient-centeredness.32 Based on the RAM,13 the 
RPM24 consists of 2 rating rounds interspersed with a discussion round. We solicited input 
from Duchenne families using ExpertLens™, a previously evaluated online modified-Delphi 
platform.30,33 We tested our approach to data collection and face validity of our measure of 
patient-centeredness during a pilot test in which a group of 8 individuals with DMD and 
caregivers completed all 3 modified-Delphi rounds and shared their feedback by 
participating in a telephone interview. Participants were consented when they logged into 
ExpertLens for the first time.
The RAND/PPMD Patient-Centeredness Method
In round 1, participants reviewed, rated, and commented on 19 statements summarizing 
guidance on endocrine and bone health management from the 2018 care considerations, 
covering delayed vertical growth, weight management, bone health, and delayed puberty 
(see online Appendix A for care statements). Because this was the first time the RPM was 
used, we did not include all care considerations covering these topics. We used plain 
language to describe each care consideration, having solicited input from our advisory board 
and Duchenne families about how to increase readability. We included the clinical rationale 
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for each care consideration, what the process of following the guidance may entail, and any 
relevant additional information, including treatment burden (Figure 1).
Participants used 9-point Likert scales to rate patient-centeredness, operationalized as the 
importance and acceptability, of each care consideration. We defined importance as the 
extent to which a consideration is likely to be consistent with the preferences, needs, and 
values of Duchenne families in general. We defined acceptability as the extent to which the 
process of following a given care consideration is likely to be consistent with available 
resources (e.g., time and finances) and with the ethical standards of Duchenne families. 
Focusing on the experiences of Duchenne families in general is consistent with what 
clinicians are asked to do when they rate appropriateness and necessity in the RAM. We 
developed these scales based on the GRADE Evidence to Decision Framework20 and with 
input from the study advisory board. We instructed participants to explain their ratings and 
list factors that most powerfully influenced their responses. To help participants comment 
about Duchenne families in general, we gave them results of a previous survey we conducted 
with Duchenne families about their main reasons (as well as barriers and facilitators) for 
seeking care for each aspect of DMD care included in our study.34 Round 1 was open from 
March 12, 2018, to March 21, 2018.
In round 2, participants reviewed bar charts showing their own responses in relation to the 
group’s distribution of round 1 responses (Figure 2). Below each chart, we displayed simple, 
color-coded statements describing whether agreement was reached and whether the panel 
judged each care consideration as important/acceptable, of uncertain importance/
acceptability, or not important/not acceptable. We analyzed ratings using the RAM’s 
approach to calculating consensus.13 We also thematically analyzed round 1 rationale 
comments and displayed comment summaries in round 2 (see below). Finally, participants 
discussed round 1 results using asynchronous and moderated discussion boards; comments 
were partially anonymous, as we used IDs that only revealed whether a participant was an 
individual with DMD or a caregiver. Round 2 was open from March 26, 2018, to April 4, 
2018.
In round 3, participants revised their original ratings based on round 2 feedback and 
discussion of round 1 results. Round 3 was open from April 4, 2018, to April 24, 2018.
Data Analysis
To determine the patient-centeredness of the care considerations, we used a 2-step analytic 
approach developed in previous ExpertLens studies35,36 (Figure 3). We first used round 3 
ratings and RAM to determine if participants in each panel agreed on the importance and 
acceptability of each care consideration. We then looked at the ratings across panels and 
considered a care consideration to be patient-centered if it was deemed important and 
acceptable by both panels. To assess the reliability of importance and acceptability 
determinations between panels, we calculated the pairwise agreement and kappa 
coefficients. We prespecified that at least a 70% agreement level and a moderate level of 
kappa (.41–.60) would indicate an acceptable reliability level between panels.37
Khodyakov et al. Page 5
Med Decis Making. Author manuscript; available in PMC 2020 November 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
To better explain perceived patient-centeredness of the care considerations, we thematically 
analyzed rationale and discussion comments. As in previous ExpertLens panels,27 we 
grouped all rationale comments for a given rating criteria and care consideration based on 
the numeric ratings to which they referred; we also grouped all discussion comments based 
on the relevant care consideration. Five researchers (SG, CA, RG, ED, CC) trained by the 
principal investigator (DK) reviewed and coded all qualitative comments inductively to 
identify emergent themes that could be used to explain why a certain care consideration was 
considered important and/or acceptable. All coding results were reviewed by DK to ensure 
consistency in the way that the codebook was applied, as well as by a clinician (KK), a 
genetic counselor and Duchenne Registry director (AM), and a caregiver (BD) to ensure the 
correct interpretation of comments. Disagreements were discussed until consensus was 
achieved. In the Results section, we describe main themes and provide illustrative 
quotations, indicating whether a quotation came from an individual with DMD or a caregiver 
and noting which panel (A or B) a particular participant was part of. Online Appendix B 
provides additional illustrative quotations describing main themes.
Results
Out of 122 invited participants, 95 (78%) participated in at least 1 panel round. Of these 95 
participants, 54 (57%; 13 patients, 41 caregivers) participated in all 3 rounds, 15 (16%; 2 
patients, 13 caregivers) in any 2 rounds (2 patients, 13 caregivers), and 26 (27%; 9 patients, 
17 care givers) in only 1 round. Of 95 participants, 88 (93%) participated in round 1; 74 
(78%) reviewed round 2 discussions and, of these, 55 (74%) posted a total of 1201 
comments (mean [SD], 21.8 [34.2]; range, 1–209); and 56 (59%) participated in round 3.
By design, the majority of our 95 participants were caregivers (75%); of those, most were 
female (83%) and white (92%) (Table 1). Slightly over two-fifths of study participants 
reported living within a 50-mile radius from a clinic where individuals with DMD receive 
neuromuscular care. While almost all males with Duchenne (96%) who participated in our 
panel reported no longer being able to walk, 59% of participating parents/caregivers reported 
providing care to a child who is still ambulatory. The difference in the ambulatory status 
between these 2 groups was statistically significant (χ2 = 19.7, df = 1, P < 0.001)
There were no statistically significant differences in the demographic characteristics of 
participants and nonparticipants, including sex, ethnicity, child’s ambulatory status, and 
distance traveled to receive neuromuscular care. Participants, however, were more likely 
than nonparticipants to have higher educational attainment. While a little over 50% of 
participants had at least a bachelor’s degree, just over 25% of nonparticipants had similar 
educational levels (χ2 = 4.049, df = 1, P = 0.044; data not shown).
Ratings of Patient-Centeredness
There was no disagreement within each panel about the importance and acceptability of any 
care consideration.
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Both panels reached identical decisions on 34 of 38 rating questions (either importance or 
acceptability) (Table 2), yielding a kappa of .69, which indicates a substantial level of 
agreement.
Moreover, both panels agreed that 12 (63%) recommendations were both important and 
acceptable and 3 (16%) were of uncertain importance and acceptability. Panels reached 
different decisions on either importance or acceptability of 4 care considerations. These 
results yield a kappa coefficient of .49, indicating moderate agreement across panels on the 
ratings of importance and acceptability taken together.
Of the 15 care considerations that both panels rated similarly, 12 (80%) met our definition of 
patient-centeredness (i.e., both panels considered them important and acceptable) (Table 2). 
Of 12 patient-centered care considerations, 4 were about vertical growth, 3 were about 
weight management, 3 others were about bone health, and 2 were about puberty. The 
remaining 3 care considerations that both panels agreed on but considered of uncertain 
importance and acceptability focused on treating impaired vertical growth with hormone 
therapy.
Although no care consideration was deemed unimportant or infeasible, we have less 
confidence in the patient-centeredness of 3 care considerations about puberty and 1 care 
consideration about delayed vertical growth because of disagreement between 2 panels. 
While panel A deemed them important and acceptable, panel B considered them either of 
uncertain importance or uncertain acceptability.
Comments about Patient-Centeredness
In general, participants’ ratings of patient-centeredness seemed to be most influenced by 
quality of life considerations and the nuances of daily lives and functional limitations of 
individuals with DMD. The importance ratings were often affected by concerns related to 
the presence/absence of scientific evidence specific to DMD, considerations of self-esteem, 
tradeoffs of dealing with other effects of the disease, and subjective risk-benefit calculations. 
The ratings of acceptability were generally affected by participants’ concerns about 
insurance coverage, access to treatment, pain caused by tests/treatments, and treatment 
safety for pediatric patients. Individuals with DMD and caregivers sometimes cited different 
factors that affected their ratings the most, with the former focusing on self-esteem and 
psychological well-being and the latter stressing insurance coverage and medication side 
effects.
All 3 weight management care considerations were deemed patient-centered. Both panels 
agreed that it is important and acceptable to maintain healthy weight and to exercise, 
especially while taking glucocorticoids: “This is an important aspect of maintaining a 
healthy weight while taking Prednisone or Emflaza,” said an individual with DMD B07. 
Participants also discussed issues related to being overweight and underweight, which can 
negatively affect quality of life. “Increased weight can greatly shorten the patient’s life and 
also makes care difficult and can cause further social ostracism,” said individual with DMD 
A12. Regardless of the patient-centeredness of all weight management care considerations, 
panel A participants still raised concerns about the lack of nutritional guidance developed 
Khodyakov et al. Page 7
Med Decis Making. Author manuscript; available in PMC 2020 November 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
specifically for Duchenne. To use the words of caregiver A19, “Being given a nutritional 
plan would be a good guide to follow to know what is acceptable to eat.” Panel B 
participants discussed how disease progression and different treatments can negatively affect 
the ability to feed oneself, exercise, and attend school full-time. In addition, participants 
raised concerns about insurance coverage for physical therapy and noted the need for more 
specific guidance on which type of exercise to pursue and which to stop or avoid. (Although 
included in other sections of the 2018 DMD care considerations, we did not include this 
more specific guidance into our protocol due to concerns about participation burden.) As 
individual with DMD A10 put it, “Exercise can be risky, especially when falls happen, 
which . . . can lead to fractured bones. So even . . . with the safeguards, these risks will be 
there, but the process is still acceptable because the reward of increased quality of life is 
greater in my experience.”
All 3 bone health care considerations were deemed patient-centered. Participants stressed the 
importance of obtaining baseline bone health information even in the absence of visible 
signs of bone loss for monitoring disease progression: “Spinal imaging should be monitored 
for scoliosis and compression fractures. A baseline is needed for future comparison,” said 
caregiver B07. Participants generally viewed assessments as important for early detection of 
bone thinning and for identifying the right time to start taking vitamins and supplements, 
adjusting their dosage, or initiating bisphosphonate treatment. X-rays and dual-energy X-ray 
absorptiometry (DEXA) scans used to assess bone health were generally considered safe and 
minimally invasive. Nonetheless, some raised concerns about difficulties in transferring 
individuals with DMD to an X-ray table, the ability to lie flat on a table during procedures 
due to discomfort caused by joint contractures, and DEXA scan costs that are not always 
covered by insurance. While treatment of vertebral fractures and bone loss with intravenous 
(IV) bisphosphonates was deemed patient-centered, some participants worried about off-
label use of this drug for children, high costs of medication, and potential side effects. As 
caregiver A38 said, “It’s off label for children . . . cost, insurance coverage, safety. . . . I 
don’t feel this is something for the typical DMD family.”
Four of 8 vertical growth care considerations were deemed patient-centered, including 
guidance to periodically assess growth until puberty is complete and to work with an 
endocrinologist to identify reasons for growth delays. Both panels felt that it is important to 
identify growth delays before age 13 and that X-rays of the hand and wrist are simple 
procedures with limited risks: “a very easy and tolerable process that the boys go through 
each year. If this helps with their quality of care, it should be done in all clinics,” said 
caregiver B44. Panel B participants, however, were less optimistic about the importance of 
identifying growth delays in boys 13 and older because “you have little time to promote 
growth through treatments,” said caregiver B31. Nonetheless, as individual with DMD A10 
noted, identifying growth delays might be more acceptable after age 13 because “the older 
you get, the less stressful X-rays or other scans are.” Finally, both panels were uncertain 
about the importance and acceptability of treating growth delays in boys of different age 
groups with abnormal growth hormone stimulation tests using hormone replacement 
therapy, citing the need for daily injections, concerns about side effects, and the lack of 
evidence that this treatment works. This result, however, is consistent with the guidance in 
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the 2018 care considerations that does not recommend routine use of growth hormones to 
treat DMD-related growth delay.
While 2 of the 5 puberty-related care considerations were deemed patient-centered, 
participants generally had somewhat different opinions about assessing and treating pubertal 
delays. Panel B’s ratings were generally lower than panel A’s. Some caregivers argued that 
there are more important concerns than pubertal delays that Duchenne families worry about 
and that such assessments are invasive and require additional doctor visits. “It seems 
unnecessarily invasive, especially to boys who already have extra medical attention,” said 
caregiver B22. Nonetheless, individuals with DMD stressed the importance of self-esteem 
for boys. To use the words of individual with DMD A38, assessments “would detect delays, 
which would help the boys keep up with peers.” Indeed, testosterone treatment discussions 
highlighted the tension between the importance of addressing emotional and social isolation 
that may be exacerbated by delayed puberty with the potential of negative side effects (e.g., 
mood swings) from what may be a medically unnecessary therapy. The following quotation 
from caregiver B34 summarizes the dilemma: using testosterone replacement therapy “is 
important, as long as the testosterone is monitored and does not make the boys more 
aggressive.” Participants also stressed the importance of allowing each boy to develop at his 
own pace. “Let each individual unfold uniquely, steroids destroy children’s lives for the hope 
of maintaining strength and destroys their immune system,” said individual with DMD B05 
in support of his low rating of the care consideration that focused on using testosterone 
therapy while taking glucocorticoids. The decision to initiate testosterone replacement 
therapy seemed to be largely dependent on the choice of a child or a family. Both panels, 
however, viewed as patient-centered the care consideration to slowly increase testosterone 
dosing to mimic normal pubertal development after the decision to start this therapy was 
made. Panelists cited strong scientific evidence behind dosing and the importance of starting 
with low doses to ensure patient safety.
Discussion
Using the RPM, our study showed that most care considerations our participants rated were 
deemed patient-centered. That is, patients and their caregivers identified these care 
considerations as likely to be consistent with the preferences, needs, and values—and 
aligning with available resources and ethical standards—of Duchenne families in general. 
Patient-centered care considerations include guidance about weight management and bone 
health, assessment and identification of impaired vertical growth, assessment of pubertal 
delays, and guidance about testosterone dosing for treating pubertal delays.
Our study provided somewhat less certainty about the patient-centeredness of 7 care 
considerations. The care considerations not meeting our patient-centeredness criteria, 
however, should not be automatically treated as not patient-centered. Because such care 
considerations might be highly preference sensitive, conditional, and context specific, 
individuals with DMD and their caregivers may want to discuss them with clinicians to 
assess the reasons why these care considerations were not deemed patient-centered in our 
study. Reviewing a list of potential concerns raised by our study participants can inform the 
development of patient decision aids38,39 and can help providers who do not see many 
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patients with DMD initiate discussions that focus on the aspects of care that may be 
potentially problematic to Duchenne families. Such discussions can bring patient-based 
evidence into clinical decision making40 and bridge the gap between evidence-based clinical 
care and patient values and preferences that patient-centered care seeks to achieve.25,26 
Because patient-centered care “is a quality of personal, professional, and organizational 
relationships,”41 it is created through a “give-and-take” during a patient-provider encounter. 
Knowing what Duchenne families think about the importance and acceptability of different 
care considerations already deemed clinically appropriate and necessary can help providers 
and families engage in shared decision making 42,43 informed by clinical, research, and 
patient-based evidence, as well as local context.44
The 3 care considerations that both panels agreed were of uncertain importance and 
acceptability all related to treating impaired growth with growth hormone therapy. The 
actual statement we used in the study was to reserve recombinant human growth hormone 
(rhGH) only for treating children if they had abnormal growth hormone simulation tests, 
which is consistent with the clinical guidance not to use this treatment routinely.10 Although 
such “conditional” guidance to use the therapy only under certain circumstances further 
reinforces the need for shared decision making, it may have been confusing to participants. 
On the one hand, the lower ratings of importance and acceptability may suggest that 
Duchenne families may be less supportive of this treatment. On the other hand, they may 
suggest that participants may have misunderstood that these care considerations are 
conditional. This finding highlights the need to interpret patient-centeredness ratings in the 
context of a particular care consideration and shows the importance of explaining 
conditional recommendations more clearly to participants.
Finally, only 1 panel viewed care considerations about using testosterone replacement 
therapy to treat delays in pubertal development as important and acceptable, suggesting that 
Duchenne families might have highly varying perspectives on this treatment depending on 
their values, needs, and life circumstances. In discussing the goals that individuals with 
DMD and their families want to achieve, clinicians may want to start a conversation about 
concerns raised about testosterone replacement therapy so that Duchenne families are more 
informed before initiating or refusing this therapy.
We note several limitations of our study. First, we asked participants to provide their input 
on already finalized care considerations. Ideally, patients and caregivers should provide their 
input on draft recommendations to allow guideline developers to account for patient-
centeredness determinations before finalizing the recommendations. Second, we used a 
purposive sample of individuals with DMD and their caregivers that may not be 
representative of the experiences of Duchenne families in general. We note, however, that 
the purposive sampling approach is a best practice for Delphi panels45 because their goal is 
to explore consensus among key stakeholders rather than make statistical inferences about a 
population. Moreover, our panels included a much larger number of participants with diverse 
experiences than previous efforts to solicit patient input on guide lines.46 Third, not all 
panelists participated in round 3, which could have biased our results. Attrition, however, is 
common for Delphi studies.47 Fourth, because of the nature of Duchenne, we invited more 
caregivers than adult individuals with DMD and excluded children. We could not apply the 
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RAM to determine consensus within each panel for each participant type separately because 
there were fewer than 9 responses to round 3 questions from individuals with DMD in 1 
panel. RAM requires responses from at least 9 participants.13 To highlight the difference that 
existed in their perspectives on patient-centeredness, we used the qualitative analyses. Fifth, 
although our measure of patient-centeredness was developed based on best practices for 
rating appropriateness and necessity, is consistent with the GRADE Evidence to Decision 
Framework,20 and was pilot-tested, it has not been formally validated. Finally, we used a 
conditional wording of care considerations related to treating delayed vertical growth with 
growth hormones, which may have confused some participants.
Based on the results of this study, we identified 3 topics for future research. First, if feasible, 
future studies should recruit more patients and balance the number of patients and caregivers 
to be able to better understand the difference in their perspectives. Second, to further explore 
the difference between patient and caregiver perspectives, future projects should include 
individuals with DMD younger than 18 as their perspectives may be different from older 
individuals with DMD and their caregivers. Third, although we used the RPM to explore the 
relevance of care considerations to patients and caregivers, future work can focus on 
adapting the RPM to determining 3 core components of content validity of patient-reported 
outcome measures as defined in the COSMIN framework, including relevance, 
comprehensiveness, and comprehensibility.48
Conclusions
In summary, we used the RPM, a novel approach to large-scale patient and caregiver 
involvement in the process of developing clinical guidelines, to determine the patient-
centeredness of 2018 DMD care considerations. Instead of asking participants to comment 
on clinical appropriateness and necessity of different care considerations—the 2 areas where 
they may not have enough expertise—we asked individuals with DMD and their caregivers 
to rate the extent to which specific care considerations are important and acceptable. 
Treatment acceptability/burden is not always considered by guideline developers, but 
including this information can help patients make informed decisions about their care49 and 
ultimately improve guideline adherence.50
Although we found that most DMD care considerations met the patient-centeredness 
criteria, our findings highlight the need to engage both patients and caregivers because they 
may have different views, especially on questions around sensitive issues (i.e., pubertal 
development). As individuals with DMD grow older, their input in the decisions about their 
own care becomes particularly crucial. Parents of younger boys with DMD noted the 
importance of seeing the perspectives of men with DMD who have already gone through 
certain stages of disease progression, arguing that their opinion is helpful not only for 
making final determinations of patient-centeredness but also for initiating treatment 
discussions with clinicians. Engaging families in guideline development, however, should 
happen before guidelines are finalized.51 Doing so may improve the quality of 
recommendations and increase their use in practice. By incorporating patient and caregiver 
perspectives, guideline developers can preemptively draw clinicians’ attention to certain 
aspects of the recommendations that might be of concern to patients and their caregivers.
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Figure 1. 
Round 1 questions. Participants are presented with a brief description of a care 
consideration, clinical reasons for and process involved in following the care consideration, 
and any additional relevant information that can help them rate its importance and 
acceptability. Participants are then asked to use 9-point Likert scales to rate the importance 
and acceptability of each care consideration and explain the factors that affected their 
responses the most using open text boxes below each rating scale.
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Figure 2. 
Round 2 feedback and discussion. The bar chart represents a distribution of participants’ 
responses. The blue line indicates a group median. The red dot indicates a participant’s own 
response. The statement presented below the chart informs participants about the group 
decision. In this particular chart, participants considered recommendation 1 to be important. 
The median was 8 on a 9-point scale. However, the participant’s own response was 7, which 
is below the median value. The table presents a summary of participants’ rationale 
comments from round 1. It lists the main reasons for providing low ratings (1–3), uncertain 
ratings (4–6), and high ratings (7–9). It also indicates whether a given reason was provided 
by individuals with Duchenne muscular dystrophy (DMD), caregivers, or both stakeholder 
groups. At the bottom of the figure are links to the discussion threads with comments posted 
in round 2 about the importance of this recommendation.
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Figure 3. 
Statistical approach to determining final group decisions about the importance and 
acceptability of care considerations. Final group decisions are determined using the RAND/
UCLA Appropriateness Method (RAM) approach.
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+
: 
a 
po
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iv
e 
de
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sio
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 m
ea
ni
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 th
at
 p
ar
tic
ip
an
ts 
w
ith
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 a
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 p
an
el
 c
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en
 c
ar
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co
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er
at
io
n 
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 b
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rta
nt
 o
r f
ea
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 m
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ag
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t d
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